Related Experiment Video

Updated: Dec 24, 2025

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

11.0K

VS-5584 Inhibits Human Osteosarcoma Cells Growth by Induction of G1- phase Arrest through Regulating PI3K/mTOR and

Jing-Yi Sun1, Ya-Jun Hou2, Hai-Juan Cui3

  • 1Department of Orthopedics, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju, Gangwon, 26426, Korea.

Current Cancer Drug Targets
|April 15, 2020
PubMed
Abstract

Insights

VS-5584 effectively inhibits human osteosarcoma cell growth by inducing cell cycle arrest and apoptosis. This novel PI3K/mTOR pathway inhibitor shows promise for osteosarcoma treatment and prevention.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The PI3K/mTOR signaling pathway is crucial in human osteosarcoma progression.
  • VS-5584 is identified as a novel PI3K/mTOR pathway inhibitor with potential anticancer activity.

Purpose of the Study:

  • To investigate the anticancer effects of VS-5584 on human osteosarcoma cells.
  • To elucidate the underlying mechanisms of VS-5584's action.

Main Methods:

  • Cytotoxicity and apoptosis assays (CCK8, flow cytometry, Western blot) were performed on U2OS and MG-63 cells.
  • Cell migration and tube formation assays were used to assess anticancer potential.
  • PI3K/mTOR and MAPK signaling pathways were analyzed.

Main Results:

  • VS-5584 inhibited osteosarcoma cell growth by inducing G1-phase arrest via p21, p27, Cyclin B1, and Cdc2 regulation.
  • VS-5584 suppressed the PI3K/mTOR pathway and triggered MAPK phosphorylation.
  • VS-5584 reduced cell migration and tube formation, down-regulating HIF-1α and VEGF.

Conclusions:

  • VS-5584 demonstrates significant anticancer effects against human osteosarcoma cells.
  • VS-5584 acts by inhibiting the PI3K/mTOR pathway and affecting cell cycle regulation.
  • VS-5584 is a potential therapeutic agent for osteosarcoma chemotherapy and chemoprevention.
Keywords:
G1-phase arrestMAPKPI3K/mTORVS-5584cytotoxicityosteosarcoma

More Related Videos

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells11:15

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

Published on: May 6, 2018

10.6K
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

4.1K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
11.5K